New research from Frost & Sullivan, Needle-Free Nanopatch Vaccines, reports that the next five to ten years will see transdermal and intradermal systems (patches and degradable implants), fast-dissolving tablet vaccines, inhalers, and pulmonary delivery methods change the vaccine industry.
According to the analysis, current forms of needle-free vaccines, such as liquid jet injection, gene guns and micro-needles, can cause cell damage and fail to consistently and directly deliver vaccines, opening the door for vaccine manufacturers to improve needle-free systems. Pharmaceutical companies are investing billions of dollars in new vaccine delivery technologies in a bid to move away from needles and syringes to skin delivery procedures.
New advancements center on addressing patient comfort levels and increasing the adoption of self-injectable therapies.
The development of thermostable vaccines with long shelf lives, such as those delivered via nanopatch, is another area of focus for many vaccine manufacturers, especially for those marketing to nations where cold-chain storage is an issue.
For more information on this study, please email Anna Zanchi, Corporate Communications.
Read the MarketWatch release